Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 122.87B +37.5% |
| Revenue (ttm) | 55.02B +4.3% |
| Net Income | 4.50B |
| EPS | 3.86 |
| Shares Out | n/a |
| PE Ratio | 27.33 |
| Forward PE | 12.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 817,314 |
| Average Volume | 2,004,069 |
| Open | 10,650 |
| Previous Close | 10,640 |
| Day's Range | 10,500 - 10,800 |
| 52-Week Range | 4,865 - 11,350 |
| Beta | 0.72 |
| RSI | 53.99 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News
TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News
Teva (TEVA) Q4 2024 Earnings Call Transcript
Teva (TEVA) Q4 2024 Earnings Call Transcript
Teva (TEVA) Q3 2024 Earnings Call Transcript
Teva (TEVA) Q3 2024 Earnings Call Transcript
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings
In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.94, after a 0.33% drop. However, over the past month, the company's stock went up by 7.18% , and in th...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3
Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3
Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) w...
Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News
Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News
Teva snaps six straight sessions of gains
Scotiabank Raises TEVA Price Target to $40 | TEVA Stock News
Scotiabank Raises TEVA Price Target to $40 | TEVA Stock News
Truist Securities Raises Teva Pharmaceutical (TEVA) Price Target to $38.00 | TEVA Stock News
Truist Securities Raises Teva Pharmaceutical (TEVA) Price Target to $38.00 | TEVA Stock News
Teva CEO Richard Francis sits down with Jim Cramer
Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk quarterly results, its growth strategy, changed in FDA development pipeline, and more.
Teva (TEVA) Q3 2025 Earnings Call Transcript
Teva (TEVA) Q3 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, ...
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion,...
Teva Pharmaceutical Industries Limited 2025 Q4 - Results - Earnings Call Presentation
2026-01-28. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2025 Q4 earnings call.
Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals
Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals
TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals
TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals
TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies
TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metri...
TEVA Aims to Double Biosimilar Revenue by 2027
TEVA Aims to Double Biosimilar Revenue by 2027